FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, D.C. 20549 | OMB APPROVAL | | | |
|--|--------------------------|-------|--|--|
| STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP | OMB Number: | 3235- | | |
| | Estimated average burden | | | |

| - 1 | _ | |
|-----|-------------------|-----------|
| | | |
| | OMB Number: | 3235-0287 |
| | Estimated average | hurdon |

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | | | - | | (. | ., | | | | | - | | | | | | | |
|--|---|--|---|---|---|---|---|-------------|---|--------|--------------------|---|-----------------------------------|--------------------------------------|---|--|--------|--|--|--|
| Name and Address of Reporting Person* Wallace James H | | | | | | 2. Issuer Name and Ticker or Trading Symbol GENTEX CORP [GNTX] | | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | |
| <u>wanace James H</u> | | | | | [] | | | | | | | | | X Director | | | 10% Ov | vner | | |
| (Last) (First) (Middle) | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 11/02/2020 | | | | | | | | | Officer below) | (give title | | Other (s below) | specify | |
| C/O 600 NORTH CENTENNIAL STREET | | | | | | | | | | | | | | | | | | | | |
| | | 4 11 | 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable | | | | | | | | | | | nlicable | | | | | | |
| (Stroot) | | _ " | 4. If Americanient, Date of Original Fried (Month/Day/rear) 6. Included of John/Group Filling (Check Applicable Line) | | | | | | | | | | | plicable | | | | | | |
| (Street) ZEELAND MI 49464 | | | | | | | | | | | | | | X Form filed by One Reporting Person | | | | | | |
| ——— | VD IVI | | 43404 | | - | | | | | | | | | | Form filed by More than One Reporting Person | | | | | |
| (City) | (S | tate) | (Zip) | | | | | | | | | | | | | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | | | |
| 1. Title of S | Security (Inst | tr. 3) | | 2. Transact | ion | 2A. D | | | 3. | | 4. Securities | | | | 5. Amo | | | | 7. Nature | |
| Date (Month/Day/Y | | | //Year) | ar) Execution Date, if any (Month/Day/Year) | | | | Disposed Of | Disposed Of (D) (Instr. 3, 4 and | | | | ially (D) | | or Indirect | of Indirect Beneficial Ownership | | | | |
| | | | | | (| | , | | | | (A) or Price | | | Reported Transaction(s) | | ''` | | (Instr. 4) | | |
| | | | | | | | | | Code | V | Amount | (D) | Price | | (Instr. 3 | | | | | |
| Common Stock 11/02/202 | | | | 020 | .0 | | M | | 7,000 | A | \$14 | \$14.3 | | 32,864 | | D | | | | |
| Common Stock 11/02/202 | | | | 020 | s 7,000 D \$28.0556 ⁽¹⁾ 25,864 | | ,864 | | D | | | | | | | | | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | | |
| | | ' | abici | | | | | | | | , converti | | | | wiieu | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | if any | emed tion Date, n/Day/Year) | 4. Transa Code (8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exer Expiration D (Month/Day/ | | ate | 7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4) | | De Se (In | Price of erivative ecurity nstr. 5) | 9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4) | ly | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | Code | v | (A) | (D) | Date Exerc | isable | Expiration Date | Title | Amou or Numb of Share | er | | | | | | |
| Employee Stock Option (Right to buy) | \$14.3 | 11/02/2020 | | | M | | | 7,000 | 11/15 | 5/2014 | 05/15/2024 | Common Stock | 7,00 | 0 | \$0.00 | 7,000 | | D | | |

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from \$28.04 to \$28.08. The price reported above reflects the weighted average sale price.

Remarks:

/s/ Kevin Nash for James H Wallace by Power of Attorney

11/03/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Kevin Nash, any successor as Chief Financial Officer of Gentex Corporation (the "Corporation"), and Scott Ryan, any successor as General counsel of Gentex Corporation, and any of their respective designees, signing singly, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Corporation, Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-infact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Corporation assuming, any of the undersigned's responsibilities to comply with Section 16 or any other provision of the Securities Exchange Act of 1934.

This Power of Attorney revokes any and all previous power of attorneys related to this subject matter, and shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Corporation, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 20th day of August, 2020.

Signature: /s/ James H Wallace Print Name: James H Wallace